Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00093184 · ClinicalTrials.gov registry record · Phase 3
Bivalirudin in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary PCI
A Phase 3 study, sponsored by The Medicines Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
NCT00093184 is a Phase 3 study that has completed, run by The Medicines Company. The registered enrollment target is 300 participants.
The verdict
NCT00093184, a Phase 3 study, has completed, sponsored by The Medicines Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate the benefit of bivalirudin in combination with clopidogrel with provisional GPIIb/IIIa inhibitor use, in reducing the bleeding complications associated with early invasive management of patients presenting with an ST Elevation Myocardial Infarction (STEMI) and undergoing primary PCI, while providing similar rates of ischemic events when compared to published results of relevant trials.
Interventions
- DRUG Angiomax (bivalirudin) anticoagulant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2004-04 |
| Est. Completion | 2005-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00093184
The ClinicalTrials.gov registry entry for NCT00093184 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Medicines Company, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Angiomax (bivalirudin) anticoagulant is the first listed.
NCT00093184 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00093184 about?
NCT00093184 is a clinical study titled "Bivalirudin in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary PCI". The purpose of this study is to demonstrate the benefit of bivalirudin in combination with clopidogrel with provisional GPIIb/IIIa inhibitor use, in reducing the bleeding complications associated with early invasive management of patients presenting with an ST Elevation Myocardial Infarction (STEMI)...
What is the current status of trial NCT00093184?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2004-04. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00093184?
The interventions under investigation include: Angiomax (bivalirudin) anticoagulant (DRUG).
Who is sponsoring clinical trial NCT00093184?
This trial is sponsored by The Medicines Company, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.